CClinicalTrials.gg
CompletedNCT01630655Updated Jun 28, 2012

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting Condition

A Phase 1 interventional study of Torrent's Felodipine Extended-Release Tablets in Healthy, sponsored by Torrent Pharmaceuticals Limited. Completed at 1 site in India. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-28.

Sponsored by Torrent Pharmaceuticals Limited · Phase 1 and Interventional

Phase
Phase 1
Study type
Interventional
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Objective:

Primary objective of the present study was to compare the single dose bioavailability of Torrent's Felodipine Extended-Release Tablets USP 10 mg and Innovator's (Mylan Pharmaceuticals Inc., USA) Felodipine Extended-Release Tablets USP 10 mg. Dosing periods were separated by a washout period of 17 days during fasting study.

Study Design:

Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Torrent Pharmaceuticals Limited is the lead sponsor of 71 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy males within the age range of 18 to 50 years.
  • A body mass index within 18-25 Kg/m2.
  • Given written informed consent to participate in the study.
  • Absence of diseases markers of HIV 1 \& 2, Hepatitis B \& C virus and RPR.
  • Absence of significant disease or clinically significant abnormal laboratory
  • values on laboratory evaluation, medical history and physical examination during the screening.
  • A normal 12-lead ECG.
  • A normal chest X-Ray.
  • Comprehension of the nature and purpose of the study and compliance with the requirements of the entire protocol.
  • No history or no evidence of hypersensitivity or idiosyncratic reactions to other nitrates or nitrites.
  • No history of allergic rash.
  • No history of significant systemic diseases.
  • No history of psychiatric disorders or addiction to any recreational drug or drug dependence.
  • No donation of blood within 56 days prior to study check-in.
  • No participation in any clinical study within the past 56 days.
  • No receipt of any prescription drugs or OTC products, with in two weeks prior to study check-in.
  • No history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to study check-in.
  • No family history of neurological disorders.
  • Not consumed alcohol and xanthine containing food and beverages, cigarettes and tobacco products, for at-list 48 hours, prior to study check-in.
  • Negative results for drugs of abuse in urine and alcohol breath analysis during check-in of each period.
  • Not consumed grape fruit juice within the 48 hours prior to study check-in.

Exclusion criteria

Exclusion Criteria:

  • Blood pressure Systolic> 140 mm Hg and \< 110 mm Hg Diastolic\< 70 mm Hg > 90 mm Hg
  • History of seizures
  • History of alcohol consumption for more than 2 units/day.
  • High caffeine or tobacco consumption
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • Any unusual or abnormal diet, for whatever reason e.g. fasting due to religious reasons.
  • Used any pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study
05

Study design

Phase
Phase 1

Interventions

  • DrugTorrent's Felodipine Extended-Release Tablets
06

What researchers measure

Primary outcomes

  1. bioequivalence based on Composite of Pharmacokinetics

    bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.

07

Study locations

1 site
  • AXIS Clinicals Limited(formerly Trident Life Sciences Ltd.)
    Miyapur, Hyderabad 500 050, India
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01630655
Lead sponsor
Torrent Pharmaceuticals Limited
Responsible party
Sponsor
First posted
Jun 28, 2012
Last update
Jun 28, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion